Clinical trials: Patients With Tumor
Hodgkin Lymphoma, Anti-PD-1 Antibody Resistant
The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.
This open-label, randomized, two-arm, phase 2 study has the primary objective of comparing the ORR obtained with Chidamide+Decitabine+Camrelizumab against that obtained with Decitabine+Camrelizumab in patients with Hodgkin…
- Trial name
- NCT04514081
- Testing
- Chidamide; Decitabine; Camrelizumab, Decitabine+Camrelizumab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese PLA General Hospital
Locally Advanced or Metastatic Solid Carcinomas, Colon Cancer
A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors
1. To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLTs) of TRK-950 as single agent 2. To establish the dose of TRK-950 recommended for future phase 2 studies
- Conditions
- Locally Advanced or Metastatic Solid Carcinomas, Colon Cancer, Cholangiocarcinoma
- Trial name
- NCT02990481
- Testing
- TRK-950
- Where
- 3 sites in United States, France
- Volunteers
- 38 people
- Sponsor
- Toray Industries, Inc
COVID19, Hematologic Malignancy
Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)
The primary objective of this phase 2, multicentric, placebo-controlled double-blind, randomized study is to evaluate the efficacy of the combination of hydroxychloroquine and azithromycine on the viral load drop at day 5 among…
- Trial name
- HYACINTHE (NCT04392128)
- Testing
- Hydroxychloroquine Sulfate 200 MG [Plaquenil], Azithromycin 250 MG Oral Capsule
- Where
- France
- Sponsor
- Institut de cancérologie Strasbourg Europe
Malignant Solid Tumour, Hematologic Malignancies
Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation
The primary objective of this study is to assess the feasibility of a multi-institutional study that collects cardiopulmonary exercise testing and 6 minute walk distance performance testing prior to a cycle of chemotherapy (or…
- Conditions
- Malignant Solid Tumour, Hematologic Malignancies, Planned Hematopoietic Cell Transplantation
- Trial name
- NCT02786628
- Testing
- Physical performance testing and patient-generated health data
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer, Hot Flashes
Acupuncture in Treating Hot Flashes in Women With Breast Cancer
RATIONALE: Acupuncture may help relieve hot flashes in women with breast cancer. It is not yet known whether acupuncture is more effective than a placebo in treating hot flashes in women with breast cancer PURPOSE: This…
- Trial name
- NCT00081965
- Testing
- acupuncture therapy, hot flashes attenuation, management of therapy complications
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
External-Beam Radiation Therapy Plus Implanted Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Trial name
- NCT00006365
- Testing
- brachytherapy, iodine I 125, radiation therapy
- Where
- 254 sites in United States, Canada
- Volunteers
- 138 people
- Sponsor
- Radiation Therapy Oncology Group
Metastatic Breast Cancer, Lung Metastases
Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions
This study will test the investigational antibody, MEDI6469 (anti-OX40), in combination with stereotactic body radiation in breast cancer patients that have liver or lung metastases and have received systemic therapy and have…
- Conditions
- Metastatic Breast Cancer, Lung Metastases, Liver Metastases
- Trial name
- OX40 Breast (NCT01862900)
- Testing
- MEDI6469
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Providence Health & Services
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003707
- Testing
- gemcitabine hydrochloride, tipifarnib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Ureter Cancer, Urethral Cancer
- Trial name
- NCT01191892
- Testing
- carboplatin, gemcitabine hydrochloride, vandetanib
- Where
- 21 sites in United Kingdom
- Volunteers
- 82 people
- Sponsor
- Cardiff University
HER2-positive Breast Cancer
Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.
The objective of this non-interventional study (NIS) is to evaluate tucatinib (TUKYSA®) combined with trastuzumab and capecitabine in adult patients with locally advanced or metastatic HER2-positive breast cancer who have been…
- Trial name
- TRACE (NCT05253911)
- Testing
- TUKYSA®
- Where
- 2 sites in Austria, Germany
- Volunteers
- 49 people
- Sponsor
- iOMEDICO AG
Esophageal Cancer
Cologne Esophageal Response Prediction Study (CERP-Study)
RATIONALE: The prognosis of patients with advanced esophageal cancer may be improved by preoperative chemoradiation. But only those patients have a benefit from this additional therapy, whose tumor shows a response after…
- Trial name
- CERP (NCT00953511)
- Testing
- ERCC1 pathways analysis
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Elfriede Bollschweiler
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
INfections in Patients Treated With CAR-T
This study includes adults with multiple myeloma or B-cell lymphoma who were/will be treated with CAR-T cell therapy at the IRCCS Azienda Ospedaliero-Universitaria di Bologna.
- Conditions
- Relapsed Multiple Myeloma, Refractory Multiple Myeloma, B-Cell Non-Hodgkin Lymphoma, Bloodstream Infections
- Trial name
- IN-CART (NCT07713511)
- Where
- Italy
- Volunteers
- 290 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lung Cancer
Radiation Therapy in Preventing Brain Metastases in Patients With Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of radiation therapy may be more effective in preventing brain metastases.
- Trial name
- NCT00006344
- Testing
- radiation therapy
- Where
- United States
- Sponsor
- Virginia Commonwealth University
Carcinoma, Non-Small-Cell Lung
Afatinib Osimertinib Sequencing NIS
This is a non-interventional, multi-country, multi-centre cohort study based on existing data from medical records of patients with EGFR mutation-positive advanced NSCLC treated with afatinib (Gi(l)otrif®) as the first-line…
- Trial name
- NCT03370770
- Testing
- Afatinib, Osimertinib
- Where
- Austria
- Volunteers
- 204 people
- Sponsor
- Boehringer Ingelheim
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma
LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
This phase Ib/II trial investigates the side effects and best dose of LY3214996 when given together with cetuximab alone or in combination with abemaciclib and to see how well they work in treating patients with colorectal cancer…
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Recurrent Colorectal Carcinoma
- Trial name
- NCT04616183
- Testing
- Abemaciclib, Cetuximab, ERK1/2 Inhibitor LY3214996
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer
This is an open label, neoadjuvant phase II study to evaluate the objective response, toxicity, and safety of trastuzumab emtansine in patients with newly diagnosed HER2-equivocal breast cancer.
- Trial name
- NATURE (NCT02725541)
- Testing
- Trastuzumab emtansine
- Where
- United States
- Sponsor
- Jenny C. Chang, MD
Advanced and/or Metastatic Solid Tumors Known to Express B7-H3
A Study of MX006 in Patients With Advanced and/or Metastatic Tumors Known to Express B7-H3
This is a Phase 1a/1b, multicenter, open-label, first-in-human (FIH) study with MX006 treatment in patients with selected tumor types known to express B7-H3.
- Trial name
- NCT07807241
- Testing
- MX006
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 120 people
- Sponsor
- Myricx Pharma Limited
Lung Cancer (Non-Small Cell)
A Phase II Study of SKB571 in Patients With Lung Cancer
This is a multicenter, phase II study. The purpose of this study is to evaluate the safety and preliminary anti-tumor activity of SKB571 in patients with advanced non-small cell lung cancer.
- Trial name
- NCT07230405
- Testing
- SKB571 for injection
- Where
- 2 sites in China
- Volunteers
- 295 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Melanoma (Skin)
Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00538005
- Testing
- bevacizumab, oxaliplatin, sorafenib tosylate
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- San Diego Pacific Oncology & Hematology Associates
Melanoma
Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma
Circulating tumor cells (CTC) are the subject of increasing interest in clinical oncology as a prognostic factor and predictor of therapeutic response.
- Trial name
- NCT01573494
- Testing
- Sampling of blood
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.